Travere Therapeutics is a commercial-stage rare disease biotech that has repositioned itself from a legacy genetic disease portfolio into a focused kidney franchise led by FILSPARI. **The core investment case is that FILSPARI is now a scaled commercial asset with accelerating adoption, evidenced by Q1 2026 sales of $105.2 million, up 88.2% year over year, and a record 993 new patient start forms.** That momentum is being reinforced by the April 13, 2026 full FDA approval in FSGS without nephrotic syndrome, where Travere currently holds a first-and-only approved position. In IgAN, competition is intensifying, but FILSPARI retains a differentiated non-immunosuppressive oral profile and benefits from a REMS simplification approved in August 2025 that lowered monitoring burden. **The May 2026 USPTO Notice of Allowance for an IgAN method-of-use patent, if issued and Orange Book listed, could protect sparsentan through October 2037, materially improving franchise durability.** Financially, Travere remains GAAP loss-making but reached first-quarter non-GAAP profitability in Q1 2026. The main debate is whether FILSPARI growth, FSGS penetration, and pipeline progress can outrun competitive IgAN crowding and offset cash demands from the $112.5 million civorebrutinib upfront payment and ongoing development spend.

Travere Therapeutics Inc (TVTX) Investment Analysis

1. Executive Summary

Travere Therapeutics, Inc. (TVTX) is a commercial-stage biopharmaceutical company focused on identifying, developing, and delivering life-changing therapies for rare kidney and genetic disorders.[1, 2, 3] The company operates primarily within the rare disease market, transitioning from a legacy portfolio of small-molecule genetic therapies toward a high-value, specialized glomerular renal franchise.[3, 4] Travere generates the overwhelming majority of its commercial revenue in the United States.[5, 6, 7] Its product portfolio is centered on two key commercial assets: FILSPARI (sparsentan) and tiopronin products (Thiola and Thiola EC).[5, 6, 8] Geographically, the company's direct sales footprint is concentrated in the United States, while its international reach is expanded through strategic licensing and collaboration agreements with CSL Vifor in Europe, Australia, and parts of the Middle East and South America, alongside Chugai Pharmaceutical in Japan, South Korea, and Taiwan.[9, 10, 11]

Core Products and Distribution Model

FILSPARI is a non-immunosuppressive, first-in-class, oral, single-molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) designed to slow kidney function decline in progressive proteinuric renal diseases.[10, 12, 13, 14] Its primary commercial indications include immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.[14, 15, 16] Tiopronin products (Thiola and Thiola EC) are enteric-coated and immediate-release formulations designed to prevent cystine stone formation in adult and pediatric patients with severe homozygous cystinuria.[8, 17, 18] Commercial revenue is transactional, recognized when specialty pharmacies and distributors dispense these therapies to patients.[3]

Primary Customers and Differentiators

The company’s primary customer base consists of specialized nephrologists managing high-risk glomerular diseases and homozygous cystinuria, alongside patients and specialized pharmacy networks.[19, 20, 21] Travere has established a unique distribution footprint using a restricted Risk Evaluation and Mitigation Strategies (REMS) program to ensure safety monitoring for sparsentan.[3, 11, 22]

Nephrologists and patients choose Travere’s therapies over alternatives due to clear mechanisms of action and favorable safety profiles:

• Avoidance of Immunosuppressive Toxicity: Traditional treatments for IgAN and FSGS relied on high-dose systemic corticosteroids or off-label immunosuppressants, which carry severe side effects, including metabolic complications and heightened infection risks.[12, 14, 23] FILSPARI targets the endothelin and angiotensin pathways directly to protect kidney function without suppressing the immune system.[13, 14]
• Monopoly Status in FSGS: Following full Food and Drug Administration (FDA) approval, FILSPARI represents the first and only approved drug specifically indicated to reduce proteinuria in FSGS patients without nephrotic syndrome, offering a targeted option where only supportive blood pressure management existed before.[14, 15, 20]
• Dosing and Compliance Advantages: Thiola EC significantly reduces the pill burden and removes the strict fasting requirements of first-generation tiopronin formulations, allowing patients to administer the drug with or without food and improving compliance in a lifelong progressive disease.[3, 8]

The table below outlines Travere’s commercial revenue performance by product segment for the quarters ended March 31, 2026, and March 31, 2025:

Product Segment	Q1 2026 Revenue (USD)	Q1 2025 Revenue (USD)	Year-over-Year Change	Key Segment Attributes & End Markets
FILSPARI (sparsentan)	\$105,152,000	\$55,881,000	+88.2%	Oral DEARA targeting primary IgAN and FSGS without nephrotic syndrome.[5, 13, 14]
Tiopronin Products	\$19,340,000	\$19,980,000	-3.2%	Generic-challenged specialty metabolic therapeutic for severe homozygous cystinuria.[5, 17]
License and Collaboration	\$2,707,000	\$5,871,000	-53.9%	Royalty and milestone revenues from international partners CSL Vifor and Chugai.[5, 9, 11]
Total Revenue	\$127,199,000	\$81,732,000	+55.6%	Consolidated rare kidney and genetic disease commercial platform.[3, 5]

2. Business Drivers & Strategic Overview

Commercial Revenue Drivers

The primary financial engine driving Travere is the commercial expansion of FILSPARI.[5, 6, 24] In the first quarter of 2026, U.S. net product sales of FILSPARI reached $105.2 million, a solid 88.2% year-over-year increase from $55.9 million in the first quarter of 2025.[5, 6] This expansion is driven by strong patient start form (PSF) momentum.[25, 26] Travere secured a record 993 new PSFs for FILSPARI in the first quarter of 2026, driven by high prescribing rates among new and repeat nephrologists.[5, 6, 24]

Conversely, tiopronin product revenue continues to decline, falling to $19.3 million in the first quarter of 2026.[5, 6] This contractive trend is driven by generic erosion.[17] In July 2024, generic manufacturer Endo, Inc. launched generic tiopronin delayed-release tablets (a direct generic alternative to Thiola EC).[17, 27] This introduction has steadily shifted volume away from Travere's branded formulation, highlighting the strategic necessity of scaling the rare kidney glomerular franchise to offset legacy attrition.[3, 4]

Core Pipeline and Growth Initiatives

To diversify its commercial concentration beyond its primary assets, Travere is pursuing three high-value pipeline expansion initiatives:

• FSGS Commercial Launch Execution: On April 13, 2026, the FDA granted full approval for FILSPARI to reduce proteinuria in adult and pediatric patients aged eight and older with FSGS without nephrotic syndrome.[14, 15, 28] This represents a significant expansion of the drug's label, and Travere initiated patient treatments within one week of approval.[6, 29] The company is leveraging its established IgAN sales infrastructure to target this underserved market.[1, 2, 7]
• Pegtibatinase in Classical Homocystinuria (HCU): Pegtibatinase is an investigational, subcutaneous enzyme replacement therapy designed to lower toxic systemic levels of total homocysteine (tHcy) in patients with classical HCU.[1, 30, 31] Following optimizations to its commercial scale-up manufacturing process, Travere restarted enrollment in the pivotal Phase 3 HARMONY study in the first quarter of 2026.[11, 26, 30] The first new patient was dosed in April 2026, and topline data are expected in the second half of 2027.[6, 29, 30] Pegtibatinase has the potential to become the first disease-modifying therapy for HCU, representing a significant long-term growth driver.[25, 30]
• Civorebrutinib In-Licensing from Everest Medicines: On June 2, 2026, Travere entered into an exclusive licensing and collaboration agreement with Everest Medicines to acquire the development and commercialization rights to civorebrutinib (EVER001) in all global territories outside of Greater China and select East/Southeast Asian markets.[32, 33, 34] Civorebrutinib is a next-generation, oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor designed for high selectivity in immune-mediated glomerular kidney diseases.[32, 33, 35] Travere paid a $112.5 million upfront fee and committed up to $1.03 billion in downstream milestones across five indications.[28, 32, 33] The company plans to evaluate the drug in primary membranous nephropathy (PMN), immune-mediated FSGS, and minimal change disease (MCD).[28, 32, 36]

Economic Moat Analysis

Travere's competitive position is protected by a multi-layered economic moat:

• High Switching Costs: Glomerular diseases like IgAN and FSGS are chronic, life-threatening, and progressive, eventually leading to end-stage kidney disease.[15, 20, 23] Once a patient is initiated and stabilized on FILSPARI, physicians are highly reluctant to switch them to alternative therapies due to risks of clinical relapse or accelerated eGFR decline.[3, 12, 20] This dynamic establishes a highly predictable, recurring revenue stream.[3]
• Intellectual Property Protection: In May 2026, the USPTO issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," covering specific methods of using FILSPARI in primary IgAN.[22, 37, 38] Upon formal issuance and FDA Orange Book listing, this method-of-use patent is expected to protect sparsentan from generic entry through October 2037.[37, 38, 39] This extension provides Travere with a durable runway to maximize the franchise's NPV.[37, 40]
• Relaxed but Protective REMS Infrastructure: FILSPARI is distributed through a restricted REMS program.[11, 22] In August 2025, the FDA approved a major REMS label update that reduced liver function monitoring from monthly to once every three months, and completely removed the monthly embryo-fetal toxicity monitoring requirement.[19, 41] While the reduction in monthly checks significantly lowers administrative hurdles for prescribing physicians and patients, the REMS framework continues to function as an entry barrier, binding specialty pharmacies and nephrologists to Travere's commercial ecosystem.[19, 20, 21]

TAM and Competitive Landscape Analysis

The total addressable market across Travere's target indications exceeds 100,000 patients in the United States, representing a multi-billion-dollar commercial opportunity.[6, 26, 29]

• IgA Nephropathy (IgAN) TAM: IgAN affects more than 70,000 addressable patients in the United States.[10, 26] The global IgAN therapeutics market is projected to grow from $878 million in 2025 to $9.7 billion by 2034, registering a CAGR of 30.5%, driven by earlier biopsy-based diagnoses and the adoption of targeted therapies.[19, 23]
• FSGS TAM: The addressable biopsy-proven FSGS population in the United States without nephrotic syndrome is estimated to be over 30,000 patients.[29, 42, 43] This segment is valued at over $1.0 billion annually.[28]

The competitive landscape in rare glomerular diseases is evolving rapidly, as detailed in the comparative matrix below:

Drug Name (Brand)	Developer	Primary Mechanism of Action	U.S. Regulatory & Launch Status	Comparative Positioning vs. FILSPARI
FILSPARI (sparsentan)	Travere Therapeutics	Dual Endothelin & Angiotensin II Receptor Antagonist (DEARA) [13, 14]	Fully Approved (IgAN: Sept 2024; FSGS: April 2026) [14, 15, 23]	Foundational, non-immunosuppressive oral therapy.[12, 14] Commands a total monopoly in FSGS [14, 15], but faces competitive crowding in IgAN.[7, 23]
Tarpeyo / Kinpeygo	Calliditas / Stada	Delayed-Release Corticosteroid (Glucocorticoid Receptor Agonist) [23, 44]	Fully Approved (Dec 2023) [23, 44]	Direct etiologic gut-targeted corticosteroid.[45] Effective at reducing protein, but limited by steroid-class toxicities and systemic side effects.[23, 44]
Vanrafia (atrasentan)	Novartis	Selective Endothelin A ($ETA$) Receptor Antagonist [23, 44]	Accelerated Approval (April 2025) [23, 41]	Potent selective endothelin block.[44] However, unlike FILSPARI, it requires co-administration with separate RAS inhibitors, increasing clinical complexity and pill burden.[13, 14, 23]
Fabhalta (iptacopan)	Novartis	Complement Factor B Inhibitor [23, 45]	Accelerated Approval (Aug 2024); eGFR 2-year data expected in 2026 [23, 41]	Oral alternative complement pathway inhibitor.[41, 45] Targets immune-mediated complement cascade, presenting a strong clinical alternative for progressive disease.[23, 41]
TRUTAKNA (atacicept)	Vera Therapeutics	Dual BAFF/APRIL Recombinant Fusion Protein [46, 47]	Accelerated Approval (July 7, 2026) [48, 49]	Subcutaneous once-weekly self-administered injection.[46, 49] Targets upstream B-cell survival cytokine signals.[46, 47] eGFR stabilization data are strong, posing a competitive threat.[46, 47]

In IgAN, Travere faces intense competition from therapeutic alternatives targeting complementary pathways.[23, 44] The recent accelerated approval of Vera's TRUTAKNA on July 7, 2026, introduces a subcutaneous option that targets pathological IgA1 production.[46, 49] In FSGS, however, Travere maintains a secure monopoly, with no near-term approved direct competitors in the clinical pipeline.[14, 15, 20] Vertex's inaxaplin is in late-stage development, but its target is restricted to genetic APOL1-mediated kidney disease (AMKD), leaving the broader idiopathic and biopsy-proven FSGS segments open to FILSPARI.[50, 51, 52]

3. Financial Performance & Valuation

Q1 2026 Earnings Performance vs. Consensus Expectations

On May 4, 2026, Travere Therapeutics reported its financial results for the first quarter ended March 31, 2026.[6, 25, 53] The results demonstrated strong underlying product demand offset by rising launch investments and a revenue miss:

• Total Revenue: Reported at $127.2 million, representing 55.6% year-over-year growth compared to $81.7 million in the first quarter of 2025.[5, 6, 54] However, this missed consensus analyst expectations of $136.2 million to $137.3 million by approximately 7.4%.[25, 54] The miss was driven by typical first-quarter commercial insurance re-authorization patterns and one fewer revenue recognition week relative to historical models.[25]
• GAAP Net Loss: Narrowed to $37.1 million, or -$0.40 per basic share, compared to a net loss of $41.2 million, or -$0.47 per basic share, in the first quarter of 2025.[5, 6] This fell short of consensus expectations calling for a GAAP loss of -$0.23 per share, representing a negative surprise of 73.9%.[25]
• Non-GAAP Adjusted Profitability: Despite the GAAP loss, Travere achieved a non-GAAP adjusted net income of $4.1 million, or $0.05 per basic share, compared to a non-GAAP adjusted net loss of $16.9 million, or -$0.19 per basic share, in the prior year's period.[5, 6, 25] This marked the company's first quarter of non-GAAP profitability, demonstrating operating leverage over non-cash amortization, stock compensation, and interest expenses.[5, 6, 25]
• Operating Expenses: Research and development (R&D) expenses increased 21.6% to $57.1 million, driven by the restart of the Phase 3 HARMONY study for pegtibatinase.[5, 25] Selling, general, and administrative (SG&A) expenses rose 32.9% to $80.3 million, driven by commercial investments in the FSGS launch and expanded IgAN field teams.[5, 25]

The table below summarizes the company's actual performance against consensus analyst forecasts:

Metric	Q1 2026 Actual	Q1 2026 Consensus	Surprise % / Absolute	Prior Year (Q1 2025)
Total Revenue	\$127.20 Million	\$137.34 Million	-7.38% (Miss)	\$81.73 Million [5, 25]
FILSPARI Sales (U.S.)	\$105.15 Million	\$105.00 Million	+0.14% (Beat)	\$55.88 Million [5]
GAAP Net Income (Loss)	\$(37.10) Million	\$(21.30) Million	-\$15.80 Million (Miss)	\$(41.23) Million [5, 25]
GAAP Basic EPS	\$(0.40)	\$(0.23)	-73.91% (Miss)	\$(0.47) [5, 25]
Non-GAAP Adjusted EPS	\$0.05	\$(0.06)	+\$0.11 (Beat)	\$(0.19) [5, 53]
Cash and Short-Term Investments	\$264.68 Million	\$260.00 Million	+\$4.68 Million	\$322.80 Million [5, 9, 55]

Guidance and Management Commentary

CFO Christopher Cline guided for moderately higher gross-to-net discount percentages for FILSPARI in 2026, projecting them in the "mid-20s" compared to 20% in 2025 as the therapeutic class expands across payer formulary structures.[7] Operating expenses are expected to grow moderately throughout 2026, driven by clinical support for the pegtibatinase trial and the commercial launch of FILSPARI in FSGS.[7]

Management emphasized that the underlying operations are approaching sustainable cash-flow breakeven, supported by a strong commercial footprint.[6, 24] CEO Eric Dube highlighted that the cumulative FILSPARI net revenue performance milestone was met for PSU vesting, which triggered a standard insider tax-withholding stock sale.[54, 56]

Balance Sheet Restructuring and Financing Activities

Following the Q1 earnings release, Travere executed two major capital transactions:

• May 2026 Convertible Debt Refinancing: To restructure its liabilities, Travere priced an upsized $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032.[57, 58, 59] Net proceeds were approximately $460.0 million.[57, 59] The company used $350.9 million of these proceeds to repurchase and retire $221.4 million of its outstanding 2.25% senior convertible notes due 2029.[57, 58, 59] While the initial conversion price was set at $64.90 per share (a 45% premium over the May 6 stock price of $44.76), this transaction pushed maturities out by three years and reduced annual cash interest expenses, improving the company's financial flexibility.[57, 59, 60]
• June 2026 Cash Commitment to Everest Medicines: Under the terms of the civorebrutinib licensing agreement, Travere paid a cash upfront fee of $112.5 million following closing in July 2026.[32, 33, 61] While adding a high-potential pipeline asset, this cash outflow reduces the company's liquid cash reserves, placing a premium on rapid commercial execution to maintain capital sufficiency.[3, 5, 32]

Valuation Analysis and Economic Model

Travere’s market valuation sits at an Enterprise Value (EV) of approximately $5.36 billion, based on a market capitalization of $5.29 billion, $327.66 million in total debt, and $264.68 million in cash.[55]

$\text{Enterprise Value (EV)} = \text{Market Cap (\$5.29B)} + \text{Total Debt (\$327.66M)} - \text{Cash (\$264.68M)} = \$5.353\text{ Billion}$

This valuation reflects the following pricing structure against consensus analyst revenue projections:

• Projected FY2026 Revenue: Analysts project consolidated revenue of $697.8 million (representing 30.1% growth over FY2025).[28] This implies a forward EV/Sales multiple of 7.7x.[28]
• Projected FY2027 Revenue: Analysts project revenue of $968.9 million (representing 38.9% growth over FY2026).[28] This implies a forward EV/Sales multiple of 5.6x.[28]
• Forward P/E Multiples: Non-GAAP adjusted net income is projected to expand to $217.0 million by FY2027 (yielding a forward adjusted P/E of 24.9x), driven by operating leverage as commercial volume scales over a fixed development base.[28]

This valuation is linked to the core commercial model of high-margin, high-touch specialty therapeutics.[3] Unlike primary-care products, rare-disease drugs command strong pricing power, with FILSPARI priced at approximately $160,000 per patient annually in the United States.[23] Consequently, small changes in the addressable patient base drive significant operating leverage directly to the bottom line once fixed R&D and commercial infrastructure costs are covered.[3, 25] The key valuation metric is the 5-year sales growth CAGR, which is driven by the expansion of sparsentan into adjacent glomerular indications and the progression of the clinical pipeline.[28, 37]

4. Risk Assessment & Macroeconomic Considerations

Company-Specific Execution Risks

The most immediate execution risk is the commercial launch of FILSPARI in the FSGS indication.[2, 7] Although approved on April 13, 2026, the label is restricted to patients without nephrotic syndrome.[14, 15] This requires nephrologists to distinguish between severe FSGS and active nephrotic syndrome, which may cause confusion and slow adoption.[13, 20] Additionally, navigating prior authorization hurdles with payers represents a near-term friction point.[3, 20] For the clinical pipeline, keeping the Phase 3 HARMONY trial for pegtibatinase on schedule is critical to meeting the 2H 2027 topline data milestone.[6, 25] This program was previously paused in late 2024 due to scale-up manufacturing issues, and any further CMC interruptions would impact the company's valuation.[26]

Competitive and Market Risks

Travere faces significant market-share erosion risks in the IgAN space.[2, 7] The recent FDA accelerated approvals of Novartis’s Vanrafia (atrasentan) and Fabhalta (iptacopan), Otsuka's Voyxact (sibeprenlimab), and Vera Therapeutics’ TRUTAKNA (atacicept) create an intensely crowded marketplace.[19, 23, 49] TRUTAKNA’s once-weekly subcutaneous dosing profile and strong 2-year eGFR stabilization data represent an upstream immunological threat that may limit the uptake of downstream hemodynamic therapies like FILSPARI.[46, 47] Because Travere’s commercial revenue is highly concentrated in a single asset (sparsentan comprising over 82% of total Q1 2026 revenue), any clinical or market-share setbacks for FILSPARI would severely impact the corporate valuation.[3, 5, 6]

Regulatory and Legal Risks

Although the USPTO issued a Notice of Allowance for the sparsentan IgAN patent, it remains at the pre-issuance stage.[38, 39] Any procedural delays, patent challenges, or failure to secure Orange Book listing would expose the company to accelerated generic filing risks prior to 2037.[37, 39] Additionally, the black-box warning for hepatotoxicity and embryo-fetal toxicity remains a structural hurdle.[11, 22] If real-world safety data identify unexpected idiosyncratic liver failure events, the FDA could restrict or suspend the REMS distribution channel.[3, 11, 22]

Balance Sheet, Capital Allocation, and Leverage Risks

While the May 2026 refinancing pushed the maturity of $221.4 million in debt to 2032, it did not eliminate the liabilities.[57, 59] The company continues to carry over $327.6 million in total debt.[55] The $112.5 million upfront cash payout to Everest Medicines for civorebrutinib, combined with clinical trial support costs, has depleted the cash reserve to approximately $152.2 million post-close (assuming no subsequent cash inflows).[5, 32, 59] If FILSPARI sales growth decelerates, Travere may face balance-sheet stress, necessitating dilutive equity raises or additional debt issuance.[25, 26, 62]

Macroeconomic Sensitivities

Travere operates in a capital-intensive sector highly sensitive to persistent macroeconomic trends:

• Cost of Capital Volatility: Persistent high-interest-rate environments increase the refinancing cost of future debt structures and compress valuations on pre-profitable biotech firms via higher weighted average cost of capital (WACC) discounts.
• Inflationary Operating Pressures: High inflation pushes clinical trial execution costs (CRO contracts, specialty labor, and active pharmaceutical ingredient manufacturing) higher, compressing operating margins during early launch phases.

Structured Risk Framework

• What Could Go Wrong: Standard of care in IgAN bypasses hemodynamic DEARAs entirely in favor of upstream immunomodulators like TRUTAKNA, causing FILSPARI sales to decline.[47] Simultaneously, the FSGS launch stalls due to high clinical friction from the restricted safety label.[3, 20]
• Early Warning Signs: A decline in quarterly New Patient Start Forms (PSFs); a widening of the FILSPARI gross-to-net discount percentage past 30% [7]; or insider selling accelerating beyond standard scheduled tax-withholding transactions.[54, 56]
• What Would Most Damage the Thesis: A successful legal challenge that invalidates the 2037 sparsentan method-of-use patent, pulling the loss of exclusivity (LOE) forward into the early 2030s [37]; or clinical trials demonstrating that competitive dual-inhibitors achieve statistically superior eGFR stabilization with zero REMS safety restrictions.

5. 5-Year Scenario Analysis

To estimate the potential five-year total return for Travere Therapeutics (TVTX) through 2031, three mathematically anchored operating cases are modeled. The current base-case share price utilized is $56.92 USD [12, 63], with 93.0 million common shares outstanding.[55, 63]

Base Case (Probability: 55%)

The Base Case assumes steady commercial execution of the core portfolio:

• Operating Rationale: FILSPARI maintains steady market share in IgAN, while international royalties from CSL Vifor and Chugai support cash flows.[9, 10, 11] The FSGS launch is moderately successful, securing steady penetration into the 30,000-patient target market.[28, 42] Pegtibatinase successfully completes Phase 3 in 2H 2027 and launches in 2029, while civorebrutinib enters Phase 3.[25, 30, 35]
• Financial Assumptions:
  • Year 5 Revenue: $1.80 Billion USD (reflecting a 5-year sales growth CAGR of ~24% from FY2025 revenue of $490.7M).[4, 9]
  • Operating Margin: 25.0% (reflecting substantial leverage as fixed R&D and launch-related SG&A expenses decline relative to scaling commercial sales).
  • GAAP Net Margin: 20.0% (yielding $360.0 Million USD in net income).
  • Diluted Share Count: Expands to 105.0 Million (reflecting mild stock-based compensation dilution and partial conversion of the 2032 notes).
  • Valuation Multiple: 25.0x P/E (standard multiple for a profitable specialty pharmaceutical company with therapeutic exclusivity).
• Valuation Bridge:
  $\text{Future Market Capitalization} = \$360.0\text{M Net Income} \times 25.0 = \$9.0\text{ Billion USD}$ $\text{Projected Share Price} = \frac{\$9.0\text{B Market Cap}}{105.0\text{M Shares}} = \$85.71\text{ USD}$ $\text{Total Return} = \frac{\$85.71 - \$56.92}{\$56.92} = 50.6\% \quad (\text{Annualized Return} = 8.5\%)$

High Case (Probability: 25%)

The High Case assumes best-in-class clinical and commercial execution:

• Operating Rationale: FILSPARI dominates the FSGS market due to lack of competitive alternatives, capturing 35% of the TAM.[15, 42] In IgAN, the 2037 method-of-use patent is securely Orange Book-listed, deterring generic entrants.[37, 38] Pegtibatinase establishes a global monopoly in HCU.[25, 30] Civorebrutinib releases blockbuster clinical data in PMN.[32, 35]
• Financial Assumptions:
  • Year 5 Revenue: $2.50 Billion USD (driven by global pediatric expansion and rapid peak adoption).
  • Operating Margin: 35.0% (favorable pricing power and optimized supply chains).
  • GAAP Net Margin: 30.0% (yielding $750.0 Million USD in net income).
  • Diluted Share Count: Stabilized at 102.0 Million due to share repurchases funded by strong free cash flow.
  • Valuation Multiple: 30.0x P/E (premium multiple reflecting high-moat specialty clinical pipelines).
• Valuation Bridge:
  $\text{Future Market Capitalization} = \$750.0\text{M Net Income} \times 30.0 = \$22.50\text{ Billion USD}$ $\text{Projected Share Price} = \frac{\$22.50\text{B Market Cap}}{102.0\text{M Shares}} = \$220.59\text{ USD}$ $\text{Total Return} = \frac{\$220.59 - \$56.92}{\$56.92} = 287.6\% \quad (\text{Annualized Return} = 31.1\%)$

Low Case (Probability: 20%)

The Low Case assumes competitive and regulatory setbacks:

• Operating Rationale: Competitive crowding in IgAN from Novartis, Otsuka, and Vera Therapeutics causes FILSPARI market share to plateau.[19, 23, 49] Payer prior authorization hurdles restrict the FSGS launch.[3, 20] Pegtibatinase fails its Phase 3 HARMONY safety endpoints, and civorebrutinib's development is discontinued.[30, 35]
• Financial Assumptions:
  • Year 5 Revenue: $800.0 Million USD (significant competitive squeeze and failure of pipeline assets).
  • Operating Margin: 12.0% (high defensive selling costs and lack of scale).
  • GAAP Net Margin: 10.0% (yielding $80.0 Million USD in net income).
  • Diluted Share Count: Dilutes to 115.0 Million (necessitated by secondary offerings to fund ongoing operational deficits).
  • Valuation Multiple: 15.0x P/E (discount multiple reflecting low-moat legacy assets).
• Valuation Bridge:
  $\text{Future Market Capitalization} = \$80.0\text{M Net Income} \times 15.0 = \$1.20\text{ Billion USD}$ $\text{Projected Share Price} = \frac{\$1.20\text{B Market Cap}}{115.0\text{M Shares}} = \$10.43\text{ USD}$ $\text{Total Return} = \frac{\$10.43 - \$56.92}{\$56.92} = -81.7\% \quad (\text{Annualized Return} = -28.9\%)$

5-Year Valuation and Trajectory Summary

Applying these operating assumptions, the table below outlines the 5-year valuation scenario analysis for Travere through 2031:

Scenario	Year 5 Revenue (USD)	GAAP Net Margin Assumption	Valuation Multiple Assumption	Current Share Price (USD)	Implied Future Share Price (USD)	5-Year Total Return	Annualized Return	Probability Weight
High Case	\$2.50 Billion	30.0% (\$750M Net Income)	30.0x P/E	\$56.92	\$220.59	287.6%	31.1%	25.0%
Base Case	\$1.80 Billion	20.0% (\$360M Net Income)	25.0x P/E	\$56.92	\$85.71	50.6%	8.5%	55.0%
Low Case	\$800.0 Million	10.0% (\$80M Net Income)	15.0x P/E	\$56.92	\$10.43	-81.7%	-28.9%	20.0%
Weighted	—	—	—	\$56.92	\$104.38	83.4%	12.9%	100.0%

Based on these probability weights, the probability-weighted 5-year share price target for Travere is $104.38 USD, representing an annualized return of 12.9%.

$\text{Weighted Price} = (\$220.59 \times 0.25) + (\$85.71 \times 0.55) + (\$10.43 \times 0.20) = \$55.15 + \$47.14 + \$2.09 = \$104.38\text{ USD}$

The projected annual share price trajectory is detailed in the table below:

Trajectory Period	Projected Share Price (USD)	Implied Annual Return	Cumulative Return vs. Year 0
Year 0 (Current)	\$56.92	—	—
Year 1 (Projected)	\$64.00	12.4%	12.4%
Year 2 (Projected)	\$72.00	12.5%	26.5%
Year 3 (Projected)	\$81.00	12.5%	42.3%
Year 4 (Projected)	\$91.00	12.3%	59.9%
Year 5 (Projected)	\$104.38	14.7%	83.4%

COMPELLING FRANCHISE OPTIONALITY

6. Qualitative Scorecard

To evaluate the operational strengths and structural risks of Travere, a qualitative scorecard is detailed below, with each metric graded on a scale of 1 to 10:

• Management Alignment (Grade: 7/10): CEO Eric Dube has led the company for over seven years, directly owning 0.16% of outstanding shares (valued at approximately $8.88 million).[64] Executive compensation is heavily weighted toward stock-based and performance-based incentives (89.9%), with a base salary of 10.1%.[64] Corporate insiders own 4.44% of outstanding common stock.[65] Standards for insider trading are governed by pre-arranged Rule 10b5-1 plans.[56, 65] While insider selling has occurred, the majority was executed automatically to cover standard tax-withholding obligations upon the vesting of performance restricted stock units (PSUs) linked to cumulative FILSPARI net revenue milestones.[54, 56] Major institutional holders include Armistice Capital, which holds a 4.21% equity stake.[65]
• Revenue Quality (Grade: 8/10): The chronic progressive nature of glomerular renal diseases creates a highly predictable, quasi-recurring patient baseline.[3] Once initiated on sparsentan, patient discontinuation rates are historically low due to the lack of alternative standard treatments, supporting long-term revenue visibility.[3] However, this predictable stream is partially offset by rising gross-to-net discount pressures and generic erosion of legacy cystinuria products.[7, 17]
• Market Position (Grade: 7/10): This score is a blend of two distinct markets.[15, 23] In FSGS, Travere commands a perfect monopoly position as the first and only approved drug.[14, 15] In IgAN, however, the company's position is pressured by competitive entrants targeting upstream B-cell and complement pathways.[23, 46, 49]
• Growth Outlook (Grade: 9/10): The addressable market is substantial, with more than 100,000 potential patients in the United States alone.[6, 29] The integration of the Phase 3 classical homocystinuria asset (pegtibatinase) and the newly in-licensed oral BTK inhibitor (civorebrutinib) provides a deep strategic runway.[30, 32, 35]
• Financial Health (Grade: 6/10): Travere holds a reasonable cash cushion of $264.7 million (plus the $25.0 million Mirum payment received post-quarter) and successfully refinanced its convertible debt out to 2032.[5, 57, 59] Nonetheless, the company remains pre-profitable under GAAP rules and carries a total debt balance of $327.7 million.[5, 55]
• Business Viability (Grade: 8/10): The medical necessity of stopping chronic kidney failure establishes high clinical durability.[3] The main operational risk is the restricted REMS distribution channel, which demands strict clinical monitoring and acts as a friction point to commercial scale.[3, 11, 22]
• Capital Allocation (Grade: 7/10): Management’s execution of the convertible debt refinancing significantly lowered debt service costs by cutting the cash interest rate to 0.50%.[57, 59] The in-licensing of civorebrutinib is a strategic move to secure future revenue, though it required a significant near-term upfront cash outlay.[28, 32]
• Analyst Sentiment (Grade: 9/10): Wall Street analysts maintain a strongly positive consensus of "Moderate Buy" to "Strong Buy".[65, 66, 67] Following the patent extension allowance and the FSGS approval, price targets were revised upward to a range of $65 to $70 by major research houses, including Wells Fargo, Citigroup, and H.C. Wainwright.[40, 65]
• Profitability (Grade: 5/10): While achieving its first adjusted non-GAAP net income of $4.1 million is a positive milestone, the business continues to generate GAAP net losses (-$37.1 million in Q1 2026).[5, 6]
• Track Record (Grade: 7/10): The commercial launch of FILSPARI in IgAN demonstrates strong commercial execution, with net product sales growing 144% in 2025.[7, 9] However, prior development setbacks and equity dilution in earlier cycles limit the long-term track record of shareholder value creation.

Blended Score

Averaging these grades yields a consolidated blended scorecard rating of 7.3 out of 10. This rating reflects a balance of strong pipeline progression and commercial execution against near-term GAAP losses and competitive market challenges.

This qualitative evaluation does not constitute financial advice or investment recommendations.

HIGH QUALITY ENGINE

7. Conclusion & Investment Thesis

The long-term investment case for Travere Therapeutics is supported by the commercial expansion of its rare kidney franchise.[3, 4] While competitive crowding in the IgAN segment is rising, the full FDA approval of FILSPARI in FSGS provides Travere with a first-mover advantage in a market segment with significant unmet clinical needs.[15, 20, 23] The May 2026 USPTO Notice of Allowance for the method-of-use patent mitigates a key tail risk, potentially extending sparsentan's commercial exclusivity through October 2037.[37, 38]

However, the company's capital deployment demands attention.[5, 32] The $112.5 million upfront fee paid to Everest Medicines for civorebrutinib reduces cash reserves, requiring steady commercial execution to avoid dilutive financing.[3, 5, 32] If Travere maintains its commercial momentum, the equity appears undervalued relative to its long-term potential.

This analysis serves analytical purposes only and does not constitute investment advice or stock recommendations.

EXECUTION AND MONOPOLY

8. Technical Analysis, Price Action & Short-Term Outlook

Travere Therapeutics (TVTX) is trading at approximately $56.92 USD, consolidating near its 52-week high of $60.10 USD and indicating strong market sentiment.[12, 66] The stock is trading comfortably above its 200-day moving average of $51.02 USD, confirming a primary uptrend, while sitting slightly below its 50-day moving average of $57.56 USD.[68] Relative strength is neutral, with a 14-day RSI of 51.77.[68] The short-term outlook suggests a consolidation phase, with the stock poised for a potential breakout once early commercial metrics for the FSGS launch are reported.[6, 15]

STRENGTH ABOVE TRENDLINE

---

1. Travere Therapeutics - Investor Relations, https://ir.travere.com/overview/default.aspx
2. Travere Therapeutics (TVTX) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026, https://public.com/stocks/tvtx/forecast-price-target
3. Travere Therapeutics (TVTX) - GreenDot Stocks, https://www.greendotstocks.com/TVTX
4. Travere Therapeutics (TVTX) Heads Into Q1 2026 With Sharply Narrowed Trailing Losses Testing Bull Case - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/travere-therapeutics-tvtx-heads-into-q1-2026-with-sharply-na
5. Financials - Quarterly Results - Travere Therapeutics - Investor Relations, https://ir.travere.com/financials/quarterly-results/default.aspx
6. Travere Therapeutics Reports First Quarter 2026 Financial Results, https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Reports-First-Quarter-2026-Financial-Results/default.aspx
7. Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins, https://seekingalpha.com/news/4554387-travere-outlines-filspari-driven-growth-and-new-fsgs-milestone-as-2026-begins
8. Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria - Travere Therapeutics - Investor Relations, https://ir.travere.com/press-releases/news-details/2019/Retrophin-Announces-FDA-Approval-of-THIOLA-EC-tiopronin-100mg-and-300mg-Tablets-for-the-Treatment-of-Cystinuria-06-28-2019/default.aspx
9. Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results, https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx
10. Travere Therapeutics Corporate Overview, https://s205.q4cdn.com/270034868/files/doc_earnings/2026/q1/presentation/Corporate-Overview-Q1-2026.pdf
11. Travere Therapeutics Provides Corporate Update and 2026 Outlook, https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Provides-Corporate-Update-and-2026-Outlook/default.aspx
12. Stock Info - Travere Therapeutics - Investor Relations, https://ir.travere.com/stock-info/default.aspx
13. Advancing Care in FSGS: A New Era in Treatment and Clinical Understanding, https://medicalaffairs.travere.com/rare-kidney-disease-news/fsgs-a-new-era-in-treatment/
14. FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis - AJMC, https://www.ajmc.com/view/fda-approves-sparsentan-for-focal-segmental-glomerulosclerosis
15. First FDA-Approved Treatment for Patients with Focal Segmental Glomerulosclerosis—A Rare Kidney Condition, https://www.fda.gov/drugs/drug-alerts-and-statements/first-fda-approved-treatment-patients-focal-segmental-glomerulosclerosis-rare-kidney-condition
16. Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress, https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Presents-Long-Term-Open-Label-Extension-Data-from-the-Phase-3-DUPLEX-Study-at-the-63rd-European-Renal-Association-ERA-2026-Congress/default.aspx
17. Endo Launches Tiopronin Delayed-Release Tablets, Generic Version of THIOLA EC, https://investor.endo.com/2024-07-15-Endo-Launches-Tiopronin-Delayed-Release-Tablets,-Generic-Version-of-THIOLA-EC-R
18. Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria - Travere Therapeutics - Investor Relations, https://ir.travere.com/press-releases/news-details/2018/Retrophin-Announces-U-S--FDA-Acceptance-of-NDA-Filing-for-the-New-Formulation-of-Thiola-tiopronin-in-the-Treatment-of-Cystinuria-11-12-2018/default.aspx
19. IgA Nephropathy (IgAN) market across the 7MM is estimated at approximately USD 878 million in 2025, analyses DelveInsight - Barchart.com, https://www.barchart.com/story/news/265111/iga-nephropathy-igan-market-across-the-7mm-is-estimated-at-approximately-usd-878-million-in-2025-analyses-delveinsight
20. FDA Approves Sparsentan for FSGS, Marking a Landmark Achievement for Patients Living with Rare Kidney Disease - NephCure, https://nephcure.org/fda-approves-sparsentan-for-fsgs-marking-a-landmark-achievement-for-patients-living-with-rare-kidney-disease/
21. Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? | AllMind AI News, https://allmind.ai/news/ae460970c2a63c88e3272933cfb414e04b94bbe3966c6a0c1a140b1331475060
22. Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy, https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Receives-Notice-of-Allowance-from-the-U-S--Patent-and-Trademark-Office-for-U-S--Patent-Application-Directed-to-Certain-Methods-of-Using-FILSPARI-sparsentan-in-IgA-Nephropathy/default.aspx
23. IgA Nephropathy Treatment Market Share, Growth Report 2033 - DataM Intelligence, https://www.datamintelligence.com/research-report/iga-nephropathy-treatment-market
24. FILSPARI growth lifts Travere (NASDAQ: TVTX) to Q1 2026 non-GAAP profit - Stock Titan, https://www.stocktitan.net/sec-filings/TVTX/8-k-travere-therapeutics-inc-reports-material-event-1b7f08d9a66c.html
25. Earnings call transcript: Travere Q1 2026 sees mixed results, stock rises - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-travere-q1-2026-sees-mixed-results-stock-rises-93CH-4657558
26. Travere Therapeutics Corporate Overview, https://s205.q4cdn.com/270034868/files/doc_presentation/2026/TVTX-Corporate-Overview-January-2026_1-12-26_FINAL.pdf
27. Endo Launches Tiopronin Delayed-Release Tablets, Generic Version of THIOLA EC®, https://www.prnewswire.com/news-releases/endo-launches-tiopronin-delayed-release-tablets-generic-version-of-thiola-ec-302196491.html
28. Travere Therapeutics (TVTX) - Trefis, https://www.trefis.com/data/companies/TVTX
29. Travere Therapeutics Reports First Quarter 2026 Financial Results, https://s205.q4cdn.com/270034868/files/doc_news/Travere-Therapeutics-Reports-First-Quarter-2026-Financial-Results-2026.pdf
30. Press release of Travere Therapeutics, Inc. dated - SEC.gov, https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/a2026q1_8-kxex991.htm
31. Travere Therapeutics Reports Third Quarter 2023 Financial Results, https://ir.travere.com/press-releases/news-details/2023/Travere-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-11-07-2023/default.aspx
32. Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Enters-Into-Exclusive-Licensing-Agreement-with-Everest-Medicines-for-Civorebrutinib-a-Potential-Best-in-Class-BTK-Inhibitor-for-Rare-Kidney-Diseases/default.aspx
33. Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib - PR Newswire, https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-close-of-exclusive-licensing-agreement-with-travere-therapeutics-for-civorebrutinib-302819372.html
34. Travere inks licensing deal worth up to $1.1B with China's Everest Medicines, https://seekingalpha.com/news/4599685-travere-inks-licensing-deal-chinas-everest
35. Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases - PR Newswire, https://www.prnewswire.com/apac/news-releases/everest-medicines-enters-into-exclusive-licensing-agreement-with-travere-therapeutics-for-civorebrutinib-a-potential-best-in-class-btk-inhibitor-for-rare-kidney-diseases-302788528.html
36. Travere Therapeutics, Everest Medicines Partner to Advance Civorebrutinib, https://www.contractpharma.com/breaking-news/travere-therapeutics-everest-medicines-partner-to-advance-civorebrutinib/
37. Travere Therapeutics Sparsentan Patent Extended to 2037 - AllSci, https://allsci.com/news/patents-ip/travere-earns-us-patent-for-sparsentan-igan-method-of-use-through-2037/
38. Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy | Nasdaq, https://www.nasdaq.com/press-release/travere-therapeutics-receives-notice-allowance-us-patent-and-trademark-office-us
39. TVTX: Expanded Kidney Franchise And IP Runway Will Shape Risk Reward Balance, https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/tvjnlfu2-tvtx-recent-regulatory-momentum-will-drive-fsgs-and-igan-market-leadership/updates/12-travere-therapeutics-sees-its-analyst-price-target-framework
40. H.C. Wainwright raises Travere Therapeutics price target to $67 By Investing.com, https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-travere-therapeutics-price-target-to-67-93CH-4722593
41. IgA Nephropathy in 2025: Year in Review - HCPLive, https://www.hcplive.com/view/iga-nephropathy-2025-year-review
42. Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS, https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Announces-Full-FDA-Approval-of-FILSPARI-sparsentan-the-First-and-Only-Approved-Medicine-for-FSGS/default.aspx
43. tvtx-20260413 - SEC.gov, https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/tvtx-20260413.htm
44. 4 Promising IgA Nephropathy Drugs in Late-Stage Trials - DelveInsight, https://www.delveinsight.com/blog/4-late-stage-iga-nephropathy-treatment-drugs
45. IgA Nephropathy | Disease Landscape & Forecast | G7 | 2024 - Clarivate, https://clarivate.com/life-sciences-healthcare/report/dlsfmd0014-2024-biopharma-iga-nephropathy-disease-landscape-forecast-g7-2024/
46. Form 8-K for Vera Therapeutics INC filed 02/26/2026, https://veratherapeutics.gcs-web.com/static-files/7439dd33-5f24-4f69-8f6d-6589c436380f
47. Vera Therapeutics Approaches July 7 PDUFA Date for Atacicept in IgA Nephropathy, https://prismmarketview.com/vera-therapeutics-approaches-july-7-pdufa-date-for-atacicept-in-iga-nephropathy/
48. Atacicept - (PIONEER) | Catalyst Events - Noah AI, https://www.noah.bio/calendar/catalyst/55
49. Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy - Stock Titan, https://www.stocktitan.net/news/VERA/vera-therapeutics-receives-fda-accelerated-approval-for-trutaknatm-3uwl22yiqkba.html
50. Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities (AMPLIFIED) - ClinicalTrials.Veeva, https://ctv.veeva.com/study/phase-2b-open-label-study-of-inaxaplin-in-participants-with-proteinuric-apol1-mediated-kidney-diseas
51. Inaxaplin to treat APOL1-mediated kidney disease moves to phase 3 trial, https://www.contemporarypediatrics.com/view/inaxaplin-to-treat-apol1-mediated-kidney-disease-moves-to-phase-3-trial
52. Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities | Vertex Clinical Trials, https://clinicaltrials.vrtx.com/studies/nct06794996
53. Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript | Seeking Alpha, https://seekingalpha.com/article/4898277-travere-therapeutics-inc-tvtx-q1-2026-earnings-call-transcript
54. Wells Fargo & Company Raises Travere Therapeutics (NASDAQ:TVTX) Price Target to $65.00 - MarketBeat, https://www.marketbeat.com/instant-alerts/wells-fargo-company-raises-travere-therapeutics-nasdaqtvtx-price-target-to-6500-2026-06-12/
55. Travere Therapeutics, Inc. (TVTX) Stock Price, Quote, News & Analysis | Seeking Alpha, https://seekingalpha.com/symbol/TVTX
56. Travere Therapeutics CFO Cline sells $115368 in company stock - Investing.com, https://www.investing.com/news/insider-trading-news/travere-therapeutics-cfo-cline-sells-115368-in-company-stock-93CH-4666054
57. EX-99.2 - SEC.gov, https://www.sec.gov/Archives/edgar/data/1438533/000119312526217100/d38424dex992.htm
58. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes, https://ir.travere.com/press-releases/news-details/2026/Travere-Prices-Upsized-475-0-Million-Convertible-Senior-Notes-Offering-to-Refinance-2029-Convertible-Notes/default.aspx
59. FWP - SEC.gov, https://www.sec.gov/Archives/edgar/data/1438533/000119312526210121/d76037dfwp.htm
60. 8-K - SEC.gov, https://www.sec.gov/Archives/edgar/data/1438533/000119312526217100/d38424d8k.htm
61. Travere Therapeutics (TVTX) Stock News | StockTitan, https://www.stocktitan.net/news/TVTX/
62. FILSPARI® (sparsentan) receives FDA approval for FSGS in patients without nephrotic syndrome, https://s205.q4cdn.com/270034868/files/doc_events/2026/TVTX-Corporate-Update-FDA-Approval-of-FILSPARI-in-FSGS-4-13-26.pdf
63. Travere Therapeutics Inc Stock Price Today | NASDAQ: TVTX Live - Investing.com, https://www.investing.com/equities/retrophin-i
64. Travere Therapeutics, Inc. (TVTX) Leadership & Management Team Analysis, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/management
65. Travere Therapeutics, Inc. $TVTX Shares Sold by Armistice Capital LLC - MarketBeat, https://www.marketbeat.com/instant-alerts/filing-travere-therapeutics-inc-tvtx-shares-sold-by-armistice-capital-llc-2026-06-18/
66. TVTX Stock Price Quote & News - Travere Therapeutics - Robinhood, https://robinhood.com/us/en/stocks/TVTX/
67. Travere Therapeutics Stock Forecast & Predictions: 1Y Price Target $58.30 | Buy or Sell NASDAQ: TVTX 2026 | WallStreetZen, https://www.wallstreetzen.com/stocks/us/nasdaq/tvtx/stock-forecast
68. TVTX Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/retrophin-i-technical